Abstract 485P
Background
Gliomas are primary tumors originating in the brain parenchyma known for their aggressive and diffusive behavior. The diagnosis is based on pathological anatomy that consists of morphological, immunohistochemical and molecular analysis. Simulating the behavior of gliomas in mathematical modeling is a powerful tool in evaluating tumor growth, as well as assisting in therapeutic decision-making.
Methods
We propose a mathematical model of continuous evolution of glioma that seeks to predict its spatio-temporal evolution through interactions of cell populations (concentration (C) of cancer cells “C_C” and dead cells “C_m”) with microenvironment (Mev) nutrients (nutrient C “ C_n”). As it is a complex phenomenon, this model takes into account the process of cell division (proliferation), death and motility. The cell division rate is assumed to follow a logistic model where the proliferation coefficient “r(C_C, C_n)” will be evaluated depending on the C of diseased cells (C_C) and nutrients (oxygen - C_n). The motility coefficient (D_c) and the Mev support capacity (C_Tmax) vary spatially as presented in the literature. For the cell death rate, it was considered that this is a function of the nutrient concentration “k_cm (C_n)” in the Mev. The non-linear system of partial differential equations, for the variables Cc (t,x), Cm (t,x), and Cn (t,x),was solved by the Method of Lines (MOL).
Results
In table we present some results for the average tumor cell population (Nc - Cells) as a function of time (in the limit cases when kn and kcm are very small and a = 0, 62.5) and comparisons with literature data. Nc - Cells for a = 0 and a = 62.5. Table: 485P
t (days) | a = 0 | a = 62.5 | ||||
Present | Ref. [1] | Ref. [2] | Present | Ref. [1] | Ref. [2] | |
1080 | 1710 | — | 1752 | 3116 | 3134 | 3126 |
Conclusions
Results for C, Nc - Cells, average tumor size and growth rate were obtained and compared to those available in the literature, showing that the presente model, with contributions that make it more rigorous and complex, appears to be physically coherent and capable of evaluating the spatio-temporal tumor growth.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
596P - Dose-individualisation of fluoropyrimidines in <italic>DPYD</italic> wild-type patients: Final results from the Alpe2U study
Presenter: Niels Heersche
Session: Poster session 16
597P - Hyperthermic intraperitoneal chemotherapy for the management of gastrointestinal cancers: An analysis of the immediate postoperative period
Presenter: Filipa Simões
Session: Poster session 16
598TiP - PRODIGE 86 (FFCD 2103 - GONO) – FOLFIRINOX SBA: Phase II randomized trial to evaluate mFOLFIRINOX and mFOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma
Presenter: Thomas Aparicio
Session: Poster session 16
599TiP - PRABITAS study: A pragmatic, randomized, phase III trial of biweekly vs. conventional use of trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer
Presenter: Tomoki Sakakida
Session: Poster session 16
600TiP - A randomized blinded phase II study of ompenaclid (RGX-202-01) vs placebo in combination with FOLFIRI plus bevacizumab (BEV) in patients (pts) with previously treated RAS mutated (RASmt) advanced/metastatic colorectal cancer (mCRC)
Presenter: Maria Elena Elez Fernandez
Session: Poster session 16
601TiP - A multicenter randomized clinical trial evaluating the negative hyperselection of patients with RAS/BRAF wild-type metastatic colorectal cancer who are eligible for anti-EGFR therapy
Presenter: Ilya Pokataev
Session: Poster session 16
602TiP - Radical concurrent chemoradiotherapy with DDP/5-FU and PD-1 antibody for non-metastatic rectal squamous cell carcinoma: A multicenter, prospective, single-arm, phase II study
Presenter: Jun Huang
Session: Poster session 16
454P - Tetrahydrocannabinol (THC) / cannabidiol (CBD) oral solution in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma: Phase Ib GEINO-1601 trial
Presenter: Juan Manuel Sepúlveda
Session: Poster session 16
455P - Phase II trial of hippocampus-avoidance whole-brain radiation therapy with simultaneous integrated boost for multiple brain metastases in non-small cell lung cancer
Presenter: Yatian Liu
Session: Poster session 16
456P - Real-world data of IDH mutant gliomas in Spain, a RETSINE: GEINO study
Presenter: Manuel Alejandro Mazariegos-Rubi
Session: Poster session 16